Insider Sells $234K in Travere Therapeutics Stock

Travere Therapeutics insider Peter Heerma sold 7,310 shares of the company's stock.

Feb. 3, 2026 at 10:07pm

Got story updates? Submit your updates here. ›

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Peter Heerma sold 7,310 shares of the company's stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $32.12, for a total value of $234,797.20. Following the completion of the transaction, the insider now owns 131,823 shares of the company's stock, valued at $4,234,154.76.

Why it matters

Insider selling can sometimes signal a lack of confidence in a company's future prospects, though it can also be for personal financial reasons unrelated to the company's performance. Travere Therapeutics is a biopharmaceutical company focused on rare kidney and genetic disorders, so insider transactions are closely watched by investors.

The details

Peter Heerma, a Travere Therapeutics insider, sold 7,310 shares of the company's stock on February 3rd. The shares were sold at an average price of $32.12, resulting in total proceeds of $234,797.20. Following the sale, Heerma still owns 131,823 shares of Travere Therapeutics stock, valued at $4,234,154.76.

  • The stock sale occurred on Tuesday, February 3rd, 2026.

The players

Peter Heerma

An insider at Travere Therapeutics, Inc., a biopharmaceutical company focused on rare kidney and genetic disorders.

Travere Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

This insider sale by Peter Heerma at Travere Therapeutics is noteworthy, as insider transactions can provide insights into a company's prospects. However, without further context, it's difficult to determine if this sale signals any broader concerns about the company's future performance.